132 related articles for article (PubMed ID: 2418164)
1. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
Hawkins MJ; Levin M; Borden EC
J Biol Response Mod; 1985 Dec; 4(6):664-8. PubMed ID: 2418164
[TBL] [Abstract][Full Text] [Related]
2. A phase I evaluation of poly(I,C)-LC in cancer patients.
Stevenson HC; Abrams PG; Schoenberger CS; Smalley RB; Herberman RB; Foon KA
J Biol Response Mod; 1985 Dec; 4(6):650-5. PubMed ID: 2418163
[TBL] [Abstract][Full Text] [Related]
3. Phase I trials of poly(I,C) complexes in advanced cancer.
Krown SE; Kerr D; Stewart WE; Field AK; Oettgen HF
J Biol Response Mod; 1985 Dec; 4(6):640-9. PubMed ID: 2418162
[TBL] [Abstract][Full Text] [Related]
4. Initial clinical trials in cancer patients of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly(ICLC)], a highly effective interferon inducer.
Levine AS; Sivulich M; Wiernik PH; Levy HB
Cancer Res; 1979 May; 39(5):1645-50. PubMed ID: 371793
[No Abstract] [Full Text] [Related]
5. Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size.
Levy HB; Riley FL; Lvovsky E; Stephen EE
Infect Immun; 1981 Nov; 34(2):416-21. PubMed ID: 6171519
[TBL] [Abstract][Full Text] [Related]
6. A preliminary trial of poly(I,C)-LC in multiple sclerosis.
McFarlin DE; Bever CT; Salazar AM; Levy HB
J Biol Response Mod; 1985 Oct; 4(5):544-8. PubMed ID: 2416885
[TBL] [Abstract][Full Text] [Related]
7. Poly(I,C)-LC as an interferon inducer in refractory multiple myeloma.
Durie BG; Levy HB; Voakes J; Jett JR; Levine AS
J Biol Response Mod; 1985 Oct; 4(5):518-24. PubMed ID: 3935757
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of poly(I,C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group.
Lampkin BC; Levine AS; Levy H; Krivit W; Hammond D
J Biol Response Mod; 1985 Oct; 4(5):531-7. PubMed ID: 2416884
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
10. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
Crane LR; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
12. Cortisol induction by poly ICLC: implications for clinical trials of interferon.
Bever CT; McFarland HF; Levy HB; McFarlin DE
Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of a complex polyriboinosinic-polyribocytidylic acid with poly-L-lysine and carboxymethyl cellulose in the treatment of children with acute leukemia and neuroblastoma: a report from the Children's Cancer Study Group.
Lampkin BC; Levine AS; Levy H; Krivit W; Hammond D
Cancer Res; 1985 Nov; 45(11 Pt 2):5904-9. PubMed ID: 2414002
[TBL] [Abstract][Full Text] [Related]
14. The effect of interferon on rabies infection of animals.
Baer GM
Tex Rep Biol Med; 1981-1982; 41():526-31. PubMed ID: 6189218
[No Abstract] [Full Text] [Related]
15. A comparison of interferon responses to poly ICLC in males and females.
Bever CT; McFarlin DE; Levy HB
J Interferon Res; 1985; 5(3):423-8. PubMed ID: 2414373
[TBL] [Abstract][Full Text] [Related]
16. Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.
Champney KJ; Levine DP; Levy HB; Lerner AM
Infect Immun; 1979 Sep; 25(3):831-7. PubMed ID: 500189
[TBL] [Abstract][Full Text] [Related]
17. Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death.
Kende M; Lupton HW; Rill WL; Gibbs P; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Aug; 31(8):1194-8. PubMed ID: 3631943
[TBL] [Abstract][Full Text] [Related]
18. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and therapeutic activity of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose [poly(I,C)-LC].
Chirigos MA; Schlick E; Ruffmann R; Budzynski W; Sinibaldi P; Gruys E
J Biol Response Mod; 1985 Dec; 4(6):621-7. PubMed ID: 4087033
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of poly(I,C)-LC in cancer patients.
Maluish AE; Reid JW; Crisp EA; Overton WR; Levy H; Foon KA; Herberman RB
J Biol Response Mod; 1985 Dec; 4(6):656-63. PubMed ID: 4087034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
